{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:09:54Z","timestamp":1792602594891,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s13555-024-01158-4","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T10:02:15Z","timestamp":1714730535000},"page":"1145-1160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04146363","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04178967","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eric L.","family":"Simpson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Chih-ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Staumont-Sall\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Shahriari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotus","family":"Mallbris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber Reck","family":"Atwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Agell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"issue":"10","key":"1158_CR1","doi-asserted-by":"publisher","first-page":"943","DOI":"10.36849\/JDD.2020.5422","volume":"19","author":"PA Lio","year":"2020","unstructured":"Lio PA, Wollenberg A, Thyssen JP, et al. Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol. 2020;19(10):943\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1158_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaad.2014.11.024","volume":"72","author":"T Hajar","year":"2015","unstructured":"Hajar T, Leshem YA, Hanifin JM, The National Eczema Association Task Force, et al. A systematic review of topical corticosteroid withdrawal (\u201csteroid addiction\u201d) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015;72(3):541-9.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1158_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242\u201355.","journal-title":"Br J Dermatol"},{"issue":"24","key":"1158_CR4","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"1158_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.19573","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450\u201363.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1158_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/bjd.17703","volume":"181","author":"A Blauvelt","year":"2019","unstructured":"Blauvelt A, Rosmarin D, Bieber T, et al. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. Br J Dermatol. 2019;181(1):196\u20137.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1158_CR7","first-page":"1643","volume":"11","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Paller AS, Siegfried EC, et al. Dupilumab demonstrates rapid and consistent improvement in extent and signs of atopic dermatitis across all anatomical regions in pediatric patients 6 years of age and older. Dermatol Ther (Heidelb). 2021;11(5):1643\u201356.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1158_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s13555-022-00694-1","volume":"12","author":"A Alexis","year":"2022","unstructured":"Alexis A, de Bruin-Weller M, Weidinger S, et al. Rapidity of improvement in signs\/symptoms of moderate-to-severe atopic dermatitis by body region with abrocitinib in the phase 3 JADE COMPARE study. Dermatol Ther (Heidelb). 2022;12(3):771\u201385.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1158_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1203475420982553","volume":"25","author":"K Ratnarajah","year":"2021","unstructured":"Ratnarajah K, Le M, Muntyanu A, et al. Inhibition of IL-13: a new pathway for atopic dermatitis. J Cutan Med Surg. 2021;25(3):315\u201328.","journal-title":"J Cutan Med Surg"},{"key":"1158_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75:54\u201362.","journal-title":"Allergy"},{"issue":"7","key":"1158_CR11","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","volume":"139","author":"LC Tsoi","year":"2019","unstructured":"Tsoi LC, Rodriguez E, Degenhardt F, et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol. 2019;139(7):1480\u20139.","journal-title":"J Invest Dermatol"},{"issue":"Suppl 1","key":"1158_CR12","first-page":"3","volume":"30","author":"A Okragly","year":"2021","unstructured":"Okragly A, Ryuzoji A, Daniels M, Patel C, Benschop R. Comparison of the affinity and in vitro activity of lebrikizumab, tralokinumab, and cendakimab. Exp Dermatol. 2021;30(Suppl 1):3\u201343.","journal-title":"Exp Dermatol"},{"issue":"4","key":"1158_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411\u201320.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1158_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","volume":"159","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. 2023;159(2):182\u201391.","journal-title":"JAMA Dermatol"},{"key":"1158_CR15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388:1080\u201391.","journal-title":"N Engl J Med"},{"issue":"6","key":"1158_CR16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/bjd\/ljad022","volume":"188","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol. 2023;188(6):740\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1158_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto TM, Cherill R, Tofte SJ, Graeber M, EASI Evaluator Group. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10(1):11\u20138.","journal-title":"Exp Dermatol"},{"issue":"3","key":"1158_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/DER.0000000000000895","volume":"33","author":"JM Hanifin","year":"2022","unstructured":"Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The eczema area and severity index-a practical guide. Dermatitis. 2022;33(3):187\u201392.","journal-title":"Dermatitis"},{"issue":"11","key":"1158_CR19","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/exd.14368","volume":"30","author":"S Ribero","year":"2021","unstructured":"Ribero S, Puglisi B, Giura MT, et al. Head and neck severity index is associated to a significant worsening of quality of life in atopic dermatitis patients. Exp Dermatol. 2021;30(11):1717\u20138.","journal-title":"Exp Dermatol"},{"issue":"3","key":"1158_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00403-013-1402-1","volume":"306","author":"FC Beikert","year":"2014","unstructured":"Beikert FC, Langenbruch AK, Radtke MA, Kornek T, Purwins S, Augustin M. Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res. 2014;306(3):279\u201386.","journal-title":"Arch Dermatol Res"},{"issue":"12","key":"1158_CR21","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","volume":"34","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Christen-Z\u00e4ch S, Taieb A, et al. ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1158_CR22","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","volume":"84","author":"CE Jo","year":"2021","unstructured":"Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84(5):1339\u201347.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1158_CR23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjd.18730","volume":"183","author":"LEM de Wijs","year":"2020","unstructured":"de Wijs LEM, Nguyen NT, Kunkeler ACM, et al. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2020;183(4):745\u20139.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1158_CR24","doi-asserted-by":"publisher","DOI":"10.25251\/skin.7.supp.272","volume":"7","author":"J Murase","year":"2023","unstructured":"Murase J, Munera M, Hong C, et al. Lebrikizumab-treated patients with atopic dermatitis had no increase in treatment-emergent adverse events of facial, head, and neck erythema compared to placebo. SKIN J Cutan Med. 2023;7(6): s272.","journal-title":"SKIN J Cutan Med"},{"issue":"9","key":"1158_CR25","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s13555-023-00980-6","volume":"13","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Shi VY, Alexis A, et al. Racial and ethnic differences in sociodemographic, clinical, and treatment characteristics among patients with atopic dermatitis in the United States and Canada: real-world data from the CorEvitas atopic dermatitis registry. Dermatol Ther (Heidelb). 2023;13(9):2045\u201361.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01158-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01158-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01158-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T13:28:22Z","timestamp":1716470902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01158-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1158"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01158-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"16 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eric Simpson: reports personal fees from AbbVie, Amgen, Arcutis, Areteia Therapeutics,, Bristol Myers Squibb \u2013 BMS, CorEvitas, Corvus, Dermira, Eli Lilly, Evelo Biosciences, FIDE, Forte Bio RX, Galderma, GlaxoSmithKline, Gilead Sciences, Impetus Healthcare, Incyte, Innovaderm Reche, Janssen, Johnson & Johnson, Kyowa Kirin Pharmaceutical Development, Leo, Merck, MJH holding (4\/29\/2021), NUMAB Therapeutics AG, Pfizer, Physicians World LLC, PRImE, Recludix Pharma, Regeneron, Roivant, Sanofi-Genzyme, Trevi therapeutics, Valeant; and grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, CorEvitas, Dermavant, Dermira, Incyte, Lilly, Kymab, Kyowa Kirin, National Jewish Health, Leo, Pfizer, Regeneron, Sanofi, Target, VeriSkin. Marjolein de Bruin-Weller: reports being a consultant, advisory board member, and\/or speaker for AbbVie, Almirall, Aslan, Amgen, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, and Sanofi. H. Chih-ho Hong has been an investigator for and\/or received honorarium from AbbVie, Amgen, Arcutis, Bausch Health, Boehringer-Ingelheim, Bristol-Meyers Squibb, Celgene, Cutanea, Dermira, Dermavant Sciences, DS Biopharma, Eli Lilly and Company, Galderma S.A., GSK, Incyte, Janssen, LEO Pharma, MedImmune, Merck, Mirimar, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi-Genzyme, and UCB. Delphine Staumont-Sall\u00e9 is speaker and\/or advisory board member and\/or investigator for AbbVie, Almirall S.A., Amgen, AstraZeneca, Eli Lilly and Company, Galderma S.A., Janssen, LEO Pharma, Novartis, Pfizer, Sanofi-Regeneron, and UCB. Andrew Blauvelt: has served as a speaker (received honoraria) for Eli Lilly and Company, Pfizer, and UCB, served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo, Lipidio, Microbion, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor, and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, DermBiont, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, UCB Pharma, and Ventyx. Kilian Eyerich is speaker and\/or advisory board member for AbbVie, Almirall S.A., Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Incyte, Janssen, LEO Pharma, Pfizer, Sanofi, and UCB Pharma and holds shares of Dermagnostix and Dermagnostix R&D. Melinda Gooderham: has been an investigator, speaker and\/or advisor for: AbbVie, Acelyrin, Amgen, Akros, Arcutis, Aristea, AnaptysBio, Apogee, Bausch Health, BMS, Boehringer Ingelheim, Cara, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, InMagene, JAMP Pharma, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Meiji, Merck, Moonlake, Nimbus, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Tarsus, Takeda, UCB, Union and Ventyx. Mona Shahriari reports consulting for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Cara, Dermavant, Incyte, Janssen, Leo Pharma, Lilly USA, Novartis, Sanofi-Genzyme, Regeneron, UCB Disease State: Psoriasis, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa; being a speaker for Abbvie, Arcutis, Bristol Myers Squibb, Lilly USA, Janssen, Dermavant, Leo Pharma, Pfizer, Sanofi-Genzyme, Regeneron, UCB Disease State: Psoriasis, Atopic Dermatitis, Alopecia Areata, Prurigo Nodularis and with regard to publications reports being consultant (honoraria) for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Galderma, Janssen, Leo Pharma, Lilly USA, Novartis, Ortho Dermatologics, Sanofi-Genzyme, Regeneron, UCB; being a speaker for Abbvie, Arcutis, Bristol Myers Squibb, Lilly USA, Janssen, Dermavant, Leo Pharma, Pfizer, UCB; and being an Investigator for AbbVie, CorEvitas Psoriasis and Atopic Dermatitis Registry, Dermira, Cara, Dermavant, Novartis, Union, Mindera. Lotus Mallbris, Amber Reck Atwater, Maria Jose Rueda, Yuxin Ding, and Zhuqing Liu are employees and stockholders of Eli Lilly and Company. Helena Agell is an employee of Almirall S.A. Jonathan I Silverberg: has received honoraria as a consultant and\/or advisory board member for Abbvie, Aldena, Amgen, AObiome, Apollo, Arcutis, Arena, Asana, Aslan, Attovia, BioMX, Biosion, Bodewell, Boehringer-Ingelheim, Bristell-Meyers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, Corevitas, Dermavant, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Invea, Kiniksa, Leo Pharma, My-Or Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sanofi-Genzyme, Shaperon, TARGET-RWE, Union, UpToDate; speaker for Abbvie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme; institution received grants from Galderma, Incyte, Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Studies were conducted in accordance with the Declaration of Helsinki and the International Council for the Harmonization of Good Clinical Practice Guideline and approved by individual institutional review boards at each participating study center. All patients provided written informed consent. Studies are registered at ClinicalTrials.gov: ADvocate 1 (NCT04146363) and ADvocate2 (NCT04178967).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}